2024-10-16 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis

**1. Performance Comparison:**

Gilead Sciences Inc. (GILD) has significantly underperformed the S&P 500 (VOO) over the given period. Its cumulative return of -11.95% pales in comparison to the S&P 500's impressive 135.82%. This translates to a staggering -147.77% divergence, placing it at the 5.09th percentile of its historical performance against the S&P 500.

**Company Overview:**

Gilead Sciences Inc. is a biopharmaceutical company that develops and commercializes medicines to treat life-threatening diseases like HIV/AIDS, hepatitis B, and cancer.

**2. Recent Price Movements:**

* **Closing Price:** $84.95
* **5-Day Moving Average:** $85.15
* **20-Day Moving Average:** $84.13
* **60-Day Moving Average:** $79.07

GILD's stock price is currently trading slightly below its 5-day and 20-day moving averages, suggesting potential downward pressure. The 60-day moving average is significantly lower, indicating a longer-term downtrend.

**3. Technical Indicators:**

* **RSI:** 55.23 - The RSI suggests the stock is in a neutral range, neither overbought nor oversold.
* **PPO:** -0.21 - The negative PPO indicates bearish momentum.
* **Delta_Previous_Relative_Divergence:** -2.63 - The negative divergence suggests a recent short-term decline in the stock's relative performance.
* **Expected Return:** 0.0% - This indicates that over a 5-year period, the stock is expected to perform similarly to the S&P 500, with no significant outperformance.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | $6.95B |
| 2024-05-08 | -3.34 | $6.69B |
| 2023-11-07 | 1.75 | $7.05B |
| 2023-08-04 | 0.84 | $6.60B |
| 2024-08-08 | 0.84 | $6.60B |

Gilead's recent earnings have been volatile, showing both positive and negative surprises. The most recent earnings release (2024-08-08) demonstrated a positive surprise with EPS reaching 1.29, exceeding analysts' expectations.

**5. News and Recent Developments:**

- Gilead's market outlook is currently mixed, with analysts expressing cautious optimism. The company's revenue growth is expected to remain subdued due to patent expirations and competition in its core HIV and hepatitis C markets.
- However, Gilead is aggressively expanding its product portfolio with investments in oncology, inflammatory diseases, and cell therapy. This diversification strategy aims to offset the impact of declining sales in older products. 
- Investors are closely watching the performance of Gilead's new products, particularly in the oncology and cell therapy spaces, to gauge the company's future growth potential.

**6. Summary:**

Gilead Sciences Inc. (GILD) has underperformed the S&P 500 significantly over the given period. While the stock exhibits neutral technical indicators, the negative PPO and recent short-term divergence suggest bearish momentum. The recent earnings release shows positive EPS, but the overall outlook remains uncertain due to challenges in core markets and the success of new products. Investors need to carefully monitor the company's performance in its newly acquired business areas and assess the potential for long-term growth.

**7. Report in English:**

This report provides a comprehensive analysis of Gilead Sciences Inc. (GILD) stock, covering its historical performance, current technical indicators, recent earnings, and future outlook. 

GILD has significantly underperformed the S&P 500 (VOO) over the given period. Its cumulative return of -11.95% pales in comparison to the S&P 500's impressive 135.82%. This translates to a staggering -147.77% divergence, placing it at the 5.09th percentile of its historical performance against the S&P 500.

Gilead's stock price is currently trading slightly below its 5-day and 20-day moving averages, suggesting potential downward pressure. The 60-day moving average is significantly lower, indicating a longer-term downtrend.

The RSI suggests the stock is in a neutral range, neither overbought nor oversold. However, the negative PPO indicates bearish momentum. The negative divergence also suggests a recent short-term decline in the stock's relative performance.

Gilead's recent earnings have been volatile, showing both positive and negative surprises. The most recent earnings release demonstrated a positive surprise with EPS reaching 1.29, exceeding analysts' expectations.

Gilead's market outlook is currently mixed, with analysts expressing cautious optimism. The company's revenue growth is expected to remain subdued due to patent expirations and competition in its core HIV and hepatitis C markets. However, Gilead is aggressively expanding its product portfolio with investments in oncology, inflammatory diseases, and cell therapy. This diversification strategy aims to offset the impact of declining sales in older products. Investors are closely watching the performance of Gilead's new products, particularly in the oncology and cell therapy spaces, to gauge the company's future growth potential.

In conclusion, GILD's performance has been underwhelming, and its future outlook remains uncertain. While the recent earnings beat provides some optimism, the company's long-term success hinges on the performance of its new products and its ability to compete effectively in a challenging market. Investors should carefully monitor Gilead's progress in its new business areas and assess its potential for long-term growth before making any investment decisions.
